Navigation Links
Oncolytics Biotech(R) Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC
Date:7/16/2009

Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented in "Molecular Cancer" with respect to REOLYSIN, the Company's expectations related to the results of trials investigating delivery of REOLYSIN, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer
2. Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration
3. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... 2015 Research and Markets ( ... Report on China,s Sodium Ibandronate Market, 2010-2019" report to ... clinic under the trade name of Bondronat in ... 1996, sodium ibandronate was approved by the FDA to come ... the trade name of Boniva. However, since drug makers later ...
(Date:9/4/2015)... , September 4, 2015 ... today announces that Hutchison MediPharma Limited ("HMP"), its ... in the second proof-of-concept ("POC") trial of fruquintinib ... cancer ("NSCLC") in China . ... succeeded in meeting the primary efficacy endpoint of ...
(Date:9/3/2015)... , Sept. 3, 2015 ... New Guide to that Market, its R&D and Sales Potentials ... assess the future of cancer-treating medicines? Visiongain,s new report gives ... stay ahead. There you discover financial data, R&D trends, opportunities, ... In our analysis you see forecasted sales to 2025 ...
Breaking Medicine Technology:Investigation Report on China's Sodium Ibandronate Market 2010-2019 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 2World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 3World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 4World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 5World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 6World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 7
... Reportlinker.com announces that a new market research ... Chinese Markets for Bladder Cancer Treatment Drugs ... , China,s demand ... a fast pace in the past decade. In ...
... , REDMOND, Wash., Nov. 3 Medical software company ... availability of FiatLux Visualize(TM) Free, advanced 2D/3D visualization software ... is available for any healthcare professional via download from ... , "There is tremendous unrealized potential in medical ...
Cached Medicine Technology:Reportlinker Adds Chinese Markets for Bladder Cancer Treatment Drugs 2Reportlinker Adds Chinese Markets for Bladder Cancer Treatment Drugs 3Reportlinker Adds Chinese Markets for Bladder Cancer Treatment Drugs 4Reportlinker Adds Chinese Markets for Bladder Cancer Treatment Drugs 5Free 2D/3D Advanced Visualization Software for CT and MRI Now Available From FiatLux Imaging 2
(Date:9/4/2015)... ... September 04, 2015 , ... ... is now available at CitiDent. CEREC is a newer method for creating restorations ... time for patients by eliminating the need for multiple appointments, CEREC produces restorations ...
(Date:9/4/2015)... ... September 04, 2015 , ... Many consumers are looking for a quick and convenient way to ... The patent-pending K Med Cups provide a quick and simple way to brew a hot ... flu or cough. As a result, they enhance comfort and health. The invention features a ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... ... on: the microbiome taking place in Hollywood, Florida October 9-10, 2015 at the ... Speakers at the 2015 symposium are doctors and researchers at the top of ...
(Date:9/4/2015)... , ... September 04, 2015 , ... Lalonde Gordon ran ... and followed up with victory in the men’s 400 meters final, with an impressive ... and Field Championships in San Jose, Costa Rica in August 2015. The 44.64 time ...
(Date:9/4/2015)... Texas (PRWEB) , ... September 04, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at ... he says are prophetic details involving the Pope’s upcoming trip to the United States. , ... details what his role with the Vatican and society is. Yisrayl also provides the meaning ...
Breaking Medicine News(10 mins):Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3Health News:Yisrayl Hawkins Writes Open Letter to Pope Francis In Light of Approaching U.S. Visit 2
... months of life, but not fetal growth, is associated with ... to a new study from The Generation R Study Group ... that low birth weight is associated with an increased risk ... fetal and infant growth patterns on this risk had not ...
... , THURSDAY, Jan. 19 (HealthDay News) -- Many ... tract, a problem that can cause serious health problems and ... said their findings show that more needs to be done ... in the esophagus, stomach or first part of the intestine ...
... growing need for family-friendly workplace policies, a new study ... with support from the Rockefeller Foundation, concludes that providing ... outcomes for working families, businesses and the public. ... Work at Rutgers, the State University of New Jersey, ...
... Reporter , THURSDAY, Jan. 19 (HealthDay News) -- The number ... for HIV infection has declined significantly, federal health officials reported ... sexual or drug-related behavior dropped from 13 percent of men ... and 8 percent, respectively, in 2010, according to the U.S. ...
... of autism is now well established, a growing body of ... in this serious developmental disorder affecting nearly one in 100 ... that low birth weight is an important environmental factor contributing ... "Our study of discordant twins -- twin pairs in which ...
... cause of blindness in the Western World. A report from ... today shows the number of new cases of blindness and ... last ten years. The study just published in ... 11,848 new cases of legal blindness. The rate of blindness ...
Cached Medicine News:Health News:Accelerated infant growth increases risk of future asthma symptoms in children 2Health News:Kidney Failure Patients Prone to GI Tract Bleeding 2Health News:Rutgers study finds paid family leave leads to positive economic outcomes 2Health News:Rutgers study finds paid family leave leads to positive economic outcomes 3Health News:More Americans Practicing Safe Sex, CDC Reports 2Health News:More Americans Practicing Safe Sex, CDC Reports 3Health News:Another clue in the mystery of autism 2Health News:Report shows risk of blindness halved over last decade 2
... 48-capillary 3730 DNA Analyzer, upgradeable to 96 ... DNA analysis. , Higher optical sensitivity ... higher-quality data at a lower cost. , ... , Optimized polymers increase your productivity without ...
... this unique offer, you can ... application. Pipetman P2 and P10 ... reagents, and P100 is perfect ... Filter Tips, which are especially ...
... is an immunochromatography based one step ... qualitative determination of Methamphetamine in human ... 1000 ng/mL. This assay has not ... care,location and is for use by ...
... The RapidAMP test is an ... test. It is,designed for qualitative determination ... above,a cut-off level of 1000 ng/mL. ... in the point of care,location and ...
Medicine Products: